Phase 3/Risankizumab/CD/Induction

Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials

ADVANCE and MOTIVATE are 2 randomized, double-masked, placebo-controlled, phase 3 trials.

Mod-severe CD with previous intolerance or inadequate response to one or more biologics (MOTIVATE) or conventional therapy (ADVANCE) were randomised to:

-IV risankizumab single dose of $600 mg \ or \ 1200 mg \ or \ placebo \ at w0,4 \ and \ 8$


<u>Coprimary endpoints:</u> clinical remission(CDAI or PRO) and endoscopic response w12.

Results:

- ADVANCE, CDAI clinical remission was 45% RISA600, 42% RISA1200 and 25% placebo, p<0.0001.
- ADVANCE endoscopic response was 40% RISA600, 32% RISA1200 and 12% placebo, p<0.0001.
- MOTIVATE, CDAI clinical remission 42% RISA 600m 40% RISA1200, 20% placebo, p<0.0001.
- MOTIVATE endoscopic response was 29% RISA600, 34% RISA1200, 11% placebo, p<0.0001.

Conclusion:

Risankizumab was effective and well tolerated as induction therapy in patients with moderately to severely active CD.



With previous

bio-failure

With previous

bio-failure

Without previous

bio-failure



Without previous

bio-failure

With previous

bio-failure

Without previous

bio-failure